Novo Nordisk shared initial results from the SELECT trial back in August, but now the full analysis—which includes data from more than 17,000 patients—has been published in The New England Journal of Medicine. 

One key difference between this new risk calculator and previous methods is that it does not consider a patient's race or ethnicity. It does, however, consider such factors as where the patient lives, their education and their income level. 

The FDA issued its own statement about the approval, highlighting the importance of taking the drug in combination with an improved diet and regular physical activity.  

The system, designed for patients with uncontrolled hypertension who are unresponsive to medication, uses ultrasound ablation to target nerves in the renal arteries, increasing blood flow. This approval comes just months after an FDA advisory panel voted in favor of the system. 

The study's authors communicated with ChatGPT-4 in both English and Japanese, noting that it appeared to struggle more with the complexities of the Japanese language. 

The new technique, audioplethysmography, can monitor a user’s heart rate and other physiological signals using headphones equipped with active noice canceling technology. It requires no additional sensors.

While it is not as well-known as some other heart-healthy diets, the portfolio diet is linked to key cardiovascular benefits. "We need to get the word out," one dietitian said. 

Will a coronary drug-coated balloon finally gain full approval from the FDA? New data presented at TCT 2023 seems to suggest it just might happen.